≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Malignant neoplasm of other and ill-defined digestive organs

DOID Endpoint Browser

C3_DIGESTIVE_ORGANS_NAS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cause of death: ICD-10 — C26
  • Cause of death: ICD-9 — 15[8-9]
  • Cause of death: ICD-8 — 15[8-9]
  • Cancer registry: Topography ICD-O-3 — C26
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

2 out of 7 registries used, show all original rules.

324

4. Check minimum number of events

None

324

5. Include endpoints

None

324

6. Filter based on genotype QC (FinnGen only)

305

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 305 138 167
Unadjusted period prevalence (%) 0.06 0.05 0.08
Median age at first event (years) 75.07 75.61 74.62

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
324
Matched controls
3237
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Z51.5
ICD-10 Finland
Palliative care
25.6
166.3
136
89
130
Kela drug reimbursment
Malignant tumour
+∞
156.2
137
*
C26.9
ICD-10 Finland
Malignant neoplasm: Ill-defined sites within the digestive system
+∞
146.2
129
*
H02AB02
ATC
dexamethasone; systemic
67.1
144.5
81
16
8140/3-C26.9
ICD-O-3
Adenocarcinoma, NOS, of gastrointestinal tract, NOS
+∞
119.3
107
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
81.8
75
*
A03FA01
ATC
metoclopramide; systemic, rectal
8.7
77.8
133
240
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
52.0
77.0
45
10
JN4BD
NOMESCO Finland
Extensive body CT
13.9
74.9
77
71
JN4AD
NOMESCO Finland
Body CT examination
11.9
74.6
87
97
C26.0
ICD-10 Finland
Malignant neoplasm: Intestinal tract, part unspecified
+∞
65.9
61
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
64.8
60
*
N02AA05
ATC
oxycodone; systemic
6.7
62.4
146
354
A04AA02
ATC
granisetron; systemic, transdermal
714.3
61.9
59
*
8000/3-C26.9
ICD-O-3
Neoplasm, malignant of gastrointestinal tract, NOS
+∞
61.4
57
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
59.2
55
*
A04AA01
ATC
ondansetron; systemic, rectal
18.0
56.5
48
31
R18
ICD-10 Finland
Ascites
25.2
55.2
40
18
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
+∞
50.3
47
*
L01BC06
ATC
capecitabine; oral
+∞
50.3
47
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
39.4
37
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
11.5
36.7
40
39
WX302
NOMESCO Finland
Thoracal epidural anesthesy
12.1
30.7
32
29
C26.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of digestive system
+∞
28.5
27
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
28.5
27
*
JAH00
NOMESCO Finland
Laparotomy
11.7
28.1
30
28
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
27.5
26
*
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
30.9
27.3
36
13
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
293.9
27.1
27
*
XX3DW
NOMESCO Finland
Time consuming IT work
7.5
27.0
41
61
WZC00
NOMESCO Finland
Treatment plan or consultation
3.6
26.9
126
481
C80.92
ICD-10 Finland
Malignant tumor without specified localization adenocarcinoma
+∞
26.4
25
*
JN3AD
NOMESCO Finland
Abdominal CT examination
4.5
23.7
68
182
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
35.2
22.8
29
9
WZC30
NOMESCO Finland
Teaching
4.1
21.7
70
204
116
Kela drug reimbursment
Prostate cancer
+∞
21.1
20
*
C80.0
ICD-10 Finland
Malignant neoplasm, primary site unknown, so stated
+∞
20.0
19
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
20.0
19
*
8936/3-C26.9
ICD-O-3
Gastrointestinal stromal tumor of gastrointestinal tract, NOS
+∞
20.0
19
*
8010/3-C26.9
ICD-O-3
Carcinoma, NOS, of gastrointestinal tract, NOS
+∞
18.9
18
*
C22.9
ICD-10 Finland
Malignant neoplasm: Liver, unspecified
+∞
18.9
18
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
74.4
18.9
21
*
JAH01
NOMESCO Finland
Laparoscopy
8.0
18.5
26
35
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
24.5
18.0
25
11
A04AA55
ATC
palonosetron, combinations; systemic
+∞
17.9
17
*
8000/3-C26.0
ICD-O-3
Neoplasm, malignant of intestinal tract, NOS
+∞
17.9
17
*
8140/3-C26.0
ICD-O-3
Adenocarcinoma, NOS, of intestinal tract, NOS
+∞
17.9
17
*
B01AB10
ATC
tinzaparin; parenteral
4.3
17.7
50
131
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
7.6
17.2
25
35
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
16.8
16
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
16.8
16
*
WF002
NOMESCO Finland
Radical radiotherapy
83.9
14.7
16
*
C49.49
ICD-10 Finland
Malignant tumor of connective tissue and soft tissue of the abdomen other or unspecified tumor
+∞
14.7
14
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
14.7
14
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
14.7
14
*
L02AE02
ATC
leuprorelin; implant, parenteral
78.5
13.7
15
*
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
78.5
13.7
15
*
JF1AB
NOMESCO Finland
Passage examination of small bowell with X-ray
35.7
13.6
17
5
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
13.6
13
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
13.6
13
*
L03AA13
ATC
pegfilgrastim; parenteral
145.7
13.5
14
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
13.3
56
192
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.5
13.1
121
628
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
12.6
12
*
C76.2
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Abdomen
+∞
12.6
12
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
12.6
12
*
189
Kela drug reimbursment
Imatinib
+∞
12.6
12
*
UJF32
NOMESCO Finland
Coloscopy
2.5
12.5
101
492
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
10.7
12.2
23
23
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
11.6
90
428
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
11.5
11
*
C25.9
ICD-10 Finland
Malignant neoplasm: Pancreas, unspecified
+∞
11.5
11
*
A79
ICPC
Malignancy NOS
+∞
11.5
11
*
L03AA02
ATC
filgrastim; parenteral
124.1
11.5
12
*
ZX120
NOMESCO Finland
Intravenous
3.9
11.4
35
97
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.3
11.0
45
151
JFB00
NOMESCO Finland
Partial resection of small intestine
29.1
10.8
14
5
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
+∞
10.5
10
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
10.5
10
*
L01XE01
ATC
[U] imatinib
+∞
10.5
10
*
Y77
ICPC
Malignant neoplasm prostate
+∞
10.5
10
*
D77
ICPC
Malignant digestive neopl other/NOS
+∞
10.5
10
*
C16.9
ICD-10 Finland
Malignant neoplasm: Stomach, unspecified
+∞
10.5
10
*
JEA00
NOMESCO Finland
Appendectomy
5.2
10.4
22
45
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.2
10.3
118
662
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.2
10.1
28
72
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
4.9
9.9
22
47
XW4AT
NOMESCO Finland
Biopsy of other inner organ with ultrasound guidance
56.7
9.7
11
*
115
Kela drug reimbursment
Breast cancer
+∞
9.4
9
*
8480/3-C26.9
ICD-O-3
Mucinous adenocarcinoma of gastrointestinal tract, NOS
+∞
9.4
9
*
JAL01
NOMESCO Finland
Laparoscopic biopsy of peritoneum
+∞
9.4
9
*
C56.00
ICD-10 Finland
Malignant tumor of the ovary without histology
+∞
9.4
9
*
C80.90
ICD-10 Finland
Malignant tumor without specified localization without histology
+∞
9.4
9
*
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
+∞
9.4
9
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
9.4
9
*
QX3AT
NOMESCO Finland
Ultrasound guided biopsy of subcutaneous tissue
37.8
9.1
11
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
37.8
9.1
11
*
B01AB05
ATC
enoxaparin; parenteral
2.1
9.0
109
619
HAB40
NOMESCO Finland
Wedge excision of mammary gland
51.4
8.7
10
*
JN4CD
NOMESCO Finland
Very extensive body CT
10.4
8.6
16
16
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.3
8.5
34
112
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.6
8.5
57
250
H01CB03
ATC
lanreotide; parenteral
92.3
8.4
9
*
176
Kela drug reimbursment
Regorafenib
+∞
8.4
8
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
8.4
8
*
C22.1
ICD-10 Finland
Malignant neoplasm: Intrahepatic bile duct carcinoma
+∞
8.4
8
*
C78.2
ICD-10 Finland
Secondary malignant neoplasm of pleura
+∞
8.4
8
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
4.1
8.3
23
59
TPX10
NOMESCO Finland
Implantation of vascular injection port
8.5
8.2
17
21
K83.1
ICD-10 Finland
Obstruction of bile duct
12.1
8.1
14
12
JA2AT
NOMESCO Finland
Abdominal puncture with ultrasound guidance
34.2
8.1
10
*
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
10.4
8.1
15
15
SPAT1255
SPAT
Intravenous administration of medicine
3.2
8.0
33
111
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
3.1
7.8
34
118
ZX090
NOMESCO Finland
Other technic of radiotherapy
46.1
7.7
9
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.0
7.7
35
125
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
9.2
7.6
15
17
A06AH03
ATC
naloxegol; oral
25.7
7.6
10
*
J94.8
ICD-10 Finland
Other specified pleural conditions
7.9
7.5
16
21
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
81.8
7.4
8
*
C25.0
ICD-10 Finland
Malignant neoplasm: Head of pancreas
+∞
7.3
7
*
C80.99
ICD-10 Finland
Malignant tumor without specified localization or histology
+∞
7.3
7
*
A04AD12
ATC
aprepitant; systemic
+∞
7.3
7
*
C78.8
ICD-10 Finland
Secondary malignant neoplasm of other and unspecified digestive organs
+∞
7.3
7
*
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
+∞
7.3
7
*
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
+∞
7.3
7
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
7.3
7
*
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
+∞
7.3
7
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
7.3
7
*
Z51.0
ICD-10 Finland
Radiotherapy session
+∞
7.3
7
*
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
+∞
7.3
7
*
WPA44, ,
SPAT
+∞
7.3
7
*
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
30.7
7.2
9
*
L02BG04
ATC
letrozole; oral
40.9
6.8
8
*
NK6AN
NOMESCO Finland
Total body bone isotope imaging
40.9
6.8
8
*
WW200, ,
SPAT
0.4
6.6
28
670
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
3.6
6.5
22
65
H01CB02
ATC
octreotide; parenteral
71.1
6.4
7
*
JFF10
NOMESCO Finland
Loop enterostomy
71.1
6.4
7
*
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
4.2
6.4
17
42
WW500
NOMESCO Finland
Blood transfusion
5.7
6.4
17
31
OAB44, ,
SPAT
0.1
6.3
*
183
C49.4
ICD-10 Finland
Malignant neoplasm: Connective and soft tissue of abdomen
+∞
6.3
6
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
6.3
6
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
6.3
6
*
L01EA01
ATC
imatinib; oral
+∞
6.3
6
*
C20.91
ICD-10 Finland
Malignant tumor of the rectum invasive carcinoma
+∞
6.3
6
*
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
+∞
6.3
6
*
C80.98
ICD-10 Finland
Malignant tumor without specified localization other specified histology
+∞
6.3
6
*
128
Kela drug reimbursment
Cancers of female genital organs
+∞
6.3
6
*
8240/3-C26.9
ICD-O-3
Neuroendocrine tumor, NOS, of gastrointestinal tract, NOS
+∞
6.3
6
*
C76.8
ICD-10 Finland
Malignant neoplasm of other and ill-defined sites: Overlapping lesion of other and ill-defined sites
+∞
6.3
6
*
C22.0
ICD-10 Finland
Malignant neoplasm: Liver cell carcinoma
+∞
6.3
6
*
C17.9
ICD-10 Finland
Malignant neoplasm: Small intestine, unspecified
+∞
6.3
6
*
Z03.1
ICD-10 Finland
Observation for suspected malignant neoplasm
10.3
6.1
11
11

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 500 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Proper column names.
  • Show details (e.g. Fisher or Chi-square test, N cases and N controls) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV not working.
  • No filters and sorters.
  • Limited amount of endpoints with TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP Concept
ln(OR) -5y
ln(OR) -1y
ln(OR) -1m
ln(OR) d0
ln(OR) +1m
ln(OR) +1y
ln(OR) +5y
MCC -5y
MCC -1y
MCC -1m
MCC d0
MCC +1m
MCC +1y
MCC +5y
Malignant neoplasm of prostate
C61 (45547509)
Malignant tumour
130 (2001600128)
Metastasis to intrahepatic bile ducts
OMOP5031661 (35226180)
Metastasis to peritoneum
OMOP5031802 (35226253)
Metastasis to retroperitoneum
OMOP5031838 (35226284)
Metastasis
OMOP4998856 (36769180)
Metastasis to liver
OMOP5000224 (36770544)
Medical Oncology
90 (38004507)
Malignant neoplasm: Intestinal tract, part unspecified
C26.0 (45532898)
Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.6 (45547522)
Secondary malignant neoplasm of other specified sites
C79.8 (45547524)
Malignant neoplasm: Ill-defined sites within the digestive system
C26.9 (45576309)
Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.7 (45595688)
Malignant tumor without specified localization adenocarcinoma
C80.92 (2000501216)
Demanding cystostatic therapy of methastized malignancy
WD125 (2001310680)
granisetron; oral, parenteral, transdermal
A04AA02 (21600494)
capecitabine
L01BC06 (21601440)
Ascites
R18 (45548949)
Malignant neoplasm: Overlapping lesion of digestive system
C26.8 (45590882)
Malignant tumor of connective tissue and soft tissue of the abdomen other or unspecified tumor
C49.49 (2000500947)
Laparoscopy
JAH01 (2001304475)
Biopsy of liver with ultrasound guidance
JJ2AT (2001305254)
Radiotherapy of metastasis
WF049 (2001310705)
Body CT examination
JN4AD (2001310897)
Extensive body CT
JN4BD (2001310899)
ondansetron; oral, parenteral, rectal
A04AA01 (21600493)
Chromogranin A [Moles/volume] in Serum or Plasma
25587-7 (3014702)
Alpha-1-Fetoprotein [Units/volume] in Serum or Plasma
19176-7 (3015916)
Cancer Ag 19-9 [Units/volume] in Serum or Plasma
24108-3 (3022914)
Metastasis to bone marrow
OMOP5031538 (35226074)
Metastasis to bone
OMOP4998978 (36769301)
Immunohistochemistry procedure
117617002 (4035726)
Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay
83083-6 (42529200)
Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay
83084-4 (42529201)
Malignant neoplasm: Liver, unspecified
C22.9 (45537795)
Palliative care
Z51.5 (45547323)
Secondary malignant neoplasm of bone and bone marrow
C79.5 (45571540)
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
D37.6 (45586102)
imatinib; oral
L01EA01 (948001)
Extensive abdominal CT
JN3BD (2001305556)
Cystostatic therapy of methastized malignancy
WD105 (2001310678)
General anaesthesia
WX402 (2001310806)
Teaching
WZC30 (2001310891)
Pathology report gross observation
24419-4 (3002256)
Protein [Mass/volume] in Pleural fluid
2882-9 (3003434)
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 (3003785)
Chloride [Moles/volume] in Serum or Plasma
2075-0 (3014576)
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 (3026910)
Bacteria identified in Isolate by Culture
43409-2 (3042936)
Oncology Clinic/Center
261QX0200X (38004268)
Liver Pathology biopsy report
65752-8 (40768441)
Body height measure
50373000 (4177340)
Body mass index
60621009 (4245997)
Adenocarcinoma, NOS, of intestinal tract, NOS
8140/3-C26.0 (44500591)
Carcinoma, NOS, of gastrointestinal tract, NOS
8010/3-C26.9 (44500771)
Adenocarcinoma, NOS, of gastrointestinal tract, NOS
8140/3-C26.9 (44501713)
Gastrointestinal stromal tumor of gastrointestinal tract, NOS
8936/3-C26.9 (44502728)
Neoplasm, malignant of intestinal tract, NOS
8000/3-C26.0 (44504804)
Neoplasm, malignant of gastrointestinal tract, NOS
8000/3-C26.9 (44504813)
Upper gastrointestinal surgery
106 (44777669)
Malignant neoplasm, primary site unspecified
C80.9 (45566620)
Pneumonia, unspecified
J18.9 (45601123)
palonosetron, combinations
A04AA55 (45893275)
Inpatient Visit
IP (9201)
Emergency Room Visit
ER (9203)
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 (3035995)
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 (3006140)
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 (3020460)
Magnesium [Moles/volume] in Serum or Plasma
2601-3 (3012095)
oxycodone; oral, parenteral
N02AA05 (21604260)
Prothrombin time (PT) actual/Normal
5894-1 (3033658)
metoclopramide; oral, parenteral, rectal
A03FA01 (21600484)
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 (3016771)
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 (3009542)
MCH [Entitic mass]
28539-5 (3035941)
Albumin [Mass/volume] in Serum or Plasma
1751-7 (3024561)
Hemoglobin [Mass/volume] in Blood
718-7 (3000963)
MCV [Entitic mean volume] in Red Blood Cells
30428-7 (3024731)
Platelets [#/volume] in Blood
26515-7 (3007461)
Erythrocytes [#/volume] in Blood
26453-1 (3026361)
INR in Blood by Coagulation assay
34714-6 (3032080)
Leukocytes [#/volume] in Blood
26464-8 (3010813)
Cathetrisation of vein
TPH04 (2001309597)
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 (3020059)
Bacteria identified in Blood by Culture
600-7 (3023368)
Creatinine [Moles/volume] in Serum or Plasma
14682-9 (3020564)
Sodium [Moles/volume] in Serum or Plasma
2951-2 (3019550)
Neutrophils [#/volume] in Blood by Automated count
751-8 (3013650)
Blood type and Crossmatch panel - Blood
34531-4 (3044640)
Potassium [Moles/volume] in Serum or Plasma
2823-3 (3023103)
Other and unspecified abdominal pain
R10.4 (45568113)
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 (3006923)
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 (40764999)
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 (3002385)
Treatment plan or consultation
WZC00 (2001310885)
CBC panel - Blood by Automated count
58410-2 (40761511)
Calcium [Moles/volume] in Serum or Plasma
2000-8 (3015377)
Blood group antibody screen [Presence] in Serum or Plasma
890-4 (3001079)
Laboratory Visit
OMOP4822461 (32036)
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 (3003338)
Short blood count panel - Blood
55429-5 (40758558)
Emergency Room and Inpatient Visit
ERIP (262)
Supplier / Service Provider
OMOP5117446 (33004)
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 (3016431)
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 (3013721)
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 (3021347)
Inpatient Hospital
21 (8717)
Epithelial cells [#/volume] in Urine
30383-4 (3000850)
Thorax X-ray examination
GD1AA (2001303617)
Physiotherapy
R4110 (2001310233)
Tissue Pathology biopsy report
66121-5 (40768804)
pH of Serum or Plasma
2753-2 (3018418)
Bacteria [Presence] in Urine
87829-8 (36304419)
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 (3016417)
Outpatient Hospital
22 (8756)
Outpatient Visit
OP (9202)
Casts [#/volume] in Urine by Automated count
51483-6 (3030467)
Emergency Medicine
93 (38004510)
General Practice
1 (38004446)
loperamide; oral
A07DA03 (21600646)
loperamide oxide; oral
A07DA05 (21600648)
tramadol; oral, parenteral, rectal
N02AX02 (21604298)
Differential panel, method unspecified - Blood
69738-3 (42870588)
Erythrocytes [#/volume] in Urine
30391-7 (3002582)
Osmolality of Urine
2695-5 (3026782)
Base excess in Venous blood by calculation
1927-3 (3002032)
General Surgery
2 (38004447)
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 (3029287)
Basophils/Leukocytes in Blood
30180-4 (3022096)
Monocytes/Leukocytes in Blood
26485-3 (3019069)
Carbon dioxide [Partial pressure] in Venous blood
2021-4 (3021447)
Glucose [Moles/volume] in Serum or Plasma
14749-6 (3013826)
Basophils [#/volume] in Blood
26444-0 (3006315)
Leukocytes [#/volume] in Urine
30405-5 (3018095)
Eosinophils/Leukocytes in Blood
26450-7 (3006504)
Lymphocytes [#/volume] in Blood
26474-7 (3019198)
Lymphocytes/Leukocytes in Blood
26478-8 (3002030)
Eosinophils [#/volume] in Blood
26449-9 (3013115)
Monocytes [#/volume] in Blood
26484-6 (3001604)
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 (3029879)
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 (2001304788)
Neutrophils/Leukocytes in Blood
26511-6 (3018010)
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 (3030306)
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 (3019800)
Obstetrics / Gynecology
16 (38004461)
Bacteria [#/volume] in Urine by Automated count
51480-2 (3031040)
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 (46236098)
aPTT in Platelet poor plasma by Coagulation assay
14979-9 (3018677)
pH of Venous blood
2746-6 (3012544)
Cancer Ag 125 [Units/volume] in Serum or Plasma
10334-1 (3037551)
dexamethasone; oral, parenteral
H02AB02 (21602730)
Normoblasts [#/volume] in Blood
715-3 (3021589)
Internal Medicine
11 (38004456)
enoxaparin; parenteral
B01AB05 (21600976)
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 (3021337)
Albumin [Presence] in Urine by Test strip
50949-7 (3029937)
Abdominal ultrasound examination
JN3AE (2001305555)
Bacteria identified in Urine by Culture
630-4 (3026008)
Erythrocytes [Presence] in Urine by Automated
53292-9 (3041096)
Essential (primary) hypertension
I10 (45591453)
Urinalysis macro (dipstick) panel - Urine
24357-6 (3037467)
Case Management Agency
251B00000X (38004193)
Nitrite [Presence] in Urine by Test strip
5802-4 (3021601)
Glucose [Presence] in Urine by Test strip
25428-4 (3009261)
EKG study
11524-6 (3013512)
Ketones [Presence] in Urine by Test strip
2514-8 (3035350)
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 (40763086)
pH of Urine
2756-5 (3015736)
12 lead EKG panel
34534-8 (3044889)
pantoprazole; oral, parenteral
A02BC02 (21600097)
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 (3013707)
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 (3013603)
Intravenous
ZX120 (2001311495)
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 (3008486)

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
195
141
33.19
233.47
3.6
1.4
199.08
2.89
ug/l
2.63
175
112
114
46
37.66
169.74
1.5
1.2
—
—
—
0
0
112
49
34.37
161.74
3.3
1.9
5161.11
17.03
u/ml
2.00
101
38
44
20
25.28
60.62
1.3
1.8
118.43
187.77
u/ml
0.14
44
20
246
1259
4.95
36.82
12.6
3.7
15.65
12.28
umol/l
1.25
239
1185
38
10
42.74
31.00
4.1
1.6
7.97
5.18
nmol/l
—
38
10
34
9
41.91
27.68
1.0
1.1
—
—
—
0
0
171
794
3.44
26.66
3.0
2.3
47.46
63.63
u/l
1.87
161
732
164
783
3.21
23.70
4.3
4.1
—
—
—
0
0
209
1149
3.30
23.66
7.9
3.8
30.51
34.91
g/l
15.74
201
1073
222
1284
3.31
22.66
15.2
5.4
5.39
4.42
e9/l
3.49
194
1099
218
1350
2.87
17.80
11.9
17.3
1.28
1.36
inr
1.11
182
1132
136
664
2.80
17.69
2.4
1.6
—
—
—
0
0
21
6
37.23
16.87
5.2
1.0
141.71
92.83
nmol/l
—
21
6
64
209
3.57
16.60
2.0
1.9
0.18
0.20
g/l
1.57
58
187
23
32
7.65
15.86
1.3
1.5
3610.38
2105.41
e6/l
0.25
13
22
141
737
2.61
15.60
2.7
2.1
—
—
—
0
0
71
257
3.25
15.59
3.3
2.0
17.67
7.59
umol/l
1.59
71
225
174
1047
2.43
13.73
3.0
2.4
—
—
estimate
—
0
0
16
5
33.50
12.68
1.4
1.0
2205.80
395.40
e6/l
—
10
5
255
1868
2.71
12.49
15.6
5.4
139.24
79.02
u/l
8.80
244
1728
37
992
0.29
12.27
1.7
2.0
1.32
1.28
mmol/l
0.06
29
806
22
24
9.74
11.18
1.3
1.5
45757.27
2340.31
e6/l
0.86
11
13
23
28
8.75
11.00
1.4
1.3
—
—
—
0
0
22
27
8.65
10.49
1.3
1.4
—
—
—
0
0
198
1356
2.18
10.36
6.7
6.2
1.20
1.21
mmol/l
0.54
168
1160
22
28
8.34
10.28
1.7
1.3
—
—
—
0
0
13
5
26.95
9.88
1.0
1.0
—
—
—
0
0
181
1212
2.11
9.86
6.2
5.5
1.20
1.21
mmol/l
1.38
174
1086
45
167
2.97
9.27
1.4
1.1
—
—
—
0
0
166
1095
2.06
9.21
6.7
5.0
2.29
3.00
%
3.67
157
1010
166
1100
2.04
9.04
6.8
5.1
0.49
0.67
%
4.24
158
1011
165
1093
2.04
8.97
6.8
5.1
9.10
9.04
%
0.09
157
1007
14
10
14.55
8.76
1.6
1.0
—
—
—
0
0
164
1094
2.01
8.65
6.6
5.1
64.41
58.89
%
6.60
156
1029
130
800
2.04
8.58
5.0
3.3
7.41
7.40
ph
1.73
104
561
164
1115
1.95
7.98
6.9
5.1
20.65
25.80
%
7.10
158
1042
71
354
2.29
7.98
1.8
1.9
—
—
—
0
0
66
320
2.33
7.91
1.2
1.2
—
—
—
0
0
126
787
1.98
7.83
6.5
4.8
—
—
—
0
0
210
1575
1.94
7.39
5.1
4.4
6.96
6.90
mmol/l
0.16
199
1499
173
1226
1.88
7.16
6.7
5.0
1.48
1.79
e9/l
6.31
151
1057
171
1213
1.86
7.00
6.7
4.9
0.04
0.04
e9/l
0.32
143
1023
169
1204
1.84
6.74
6.8
4.9
0.69
0.61
e9/l
2.36
142
1012
93
548
1.98
6.66
1.3
1.3
—
—
—
0
0
173
1249
1.82
6.54
6.9
5.0
0.16
0.21
e9/l
2.58
147
1068
75
421
2.01
6.11
2.7
1.7
29.47
29.42
s
0.03
75
404
80
474
1.91
5.54
2.2
2.5
10.98
12.44
umol/l
0.97
70
440
41
786
0.45
5.49
3.1
3.8
—
—
—
0
0
5
0
+∞
5.22
2.0
0.0
48.76
—
pmol/l
—
5
0
211
1678
1.73
5.19
4.9
4.9
1240.29
2056.44
e6/l
—
7
34
74
436
1.90
5.18
2.1
2.5
2.14
2.25
g/l
0.95
67
403
203
2398
0.59
4.87
4.1
6.4
2.63
2.53
mmol/l
0.74
172
2187
47
242
2.10
4.79
5.9
7.2
—
—
—
0
0
86
544
1.79
4.77
2.5
3.0
491.82
529.91
mosm/kgh2o
1.15
78
472
102
681
1.72
4.68
3.6
3.1
—
0.00
estimate
—
0
8
198
2339
0.60
4.50
3.8
5.5
4.51
4.42
mmol/l
0.50
171
2145
67
406
1.82
4.25
2.3
2.4
20.77
22.41
%
0.28
59
377
12
25
4.94
4.22
1.6
3.4
—
—
—
0
0
64
987
0.56
4.16
3.3
3.5
113.46
43.40
mg/l
0.70
44
655
198
2317
0.62
3.98
3.7
5.4
1.40
1.45
mmol/l
0.74
171
2099
97
664
1.66
3.97
12.9
4.4
—
—
—
0
0
199
2321
0.63
3.87
5.9
7.5
41.18
40.77
mmol/mol
0.25
176
2148
105
739
1.62
3.83
3.4
3.1
2.59
0.53
e6/l
0.89
78
548
67
1002
0.58
3.81
3.3
3.4
8.00
7.28
mmol/l
0.46
52
844
129
960
1.57
3.70
4.1
3.9
71.56
132.38
e6/l
1.10
91
693
206
2376
0.63
3.68
4.0
5.6
6.17
6.14
mmol/l
0.11
171
2134
137
1048
1.53
3.41
15.6
10.0
0.00
0.00
e9/l
0.33
112
849
117
868
1.54
3.33
3.7
3.3
56.06
177.37
e6/l
0.76
89
669
71
1019
0.61
3.33
3.8
4.1
25.08
7.05
mg/mmol
0.69
45
661
190
2209
0.66
3.25
3.4
4.7
1.35
1.26
mmol/l
1.07
162
1976
7
11
6.47
3.20
1.1
1.3
—
—
—
0
0
52
321
1.74
3.08
3.3
3.0
1.93
2.07
mmol/l
0.08
45
277
18
78
2.38
2.79
3.3
1.8
25.94
20.10
s
0.65
18
72
20
93
2.22
2.66
3.3
2.5
271.36
281.43
mg/l
0.04
14
30
61
416
1.57
2.46
2.9
3.1
2.45
2.38
e6/l
0.03
25
194
100
759
1.46
2.44
2.4
2.3
3.00
2.97
mg/l
0.05
84
645
50
331
1.60
2.29
3.1
3.1
7.38
7.39
ph
0.13
27
206
6
14
4.34
2.16
1.0
1.2
—
—
—
0
0
12
49
2.50
2.12
1.0
1.3
—
—
—
0
0
30
177
1.76
2.10
2.0
3.4
0.43
0.34
%
0.18
14
44
31
186
1.74
2.06
4.8
3.4
—
—
—
0
0
31
186
1.74
2.06
1.2
1.4
—
—
—
0
0
53
365
1.54
2.05
5.2
6.1
11.94
11.18
kpa
0.55
53
349
53
365
1.54
2.05
5.2
6.1
5.05
5.11
kpa
0.23
53
349
53
366
1.53
2.03
5.3
6.1
7.43
7.41
ph
0.63
27
219
52
358
1.54
2.02
4.8
6.2
1.56
1.15
mmol/l
0.34
45
291
12
51
2.40
1.97
2.0
3.1
—
—
—
0
0
23
387
0.56
1.93
1.1
1.3
1.62
10.57
u/ml
—
6
129
110
883
1.37
1.89
2.9
3.5
—
—
—
0
0
13
59
2.25
1.86
1.5
1.6
38.75
38.06
umol/l
—
8
50
37
240
1.61
1.85
1.3
1.3
—
—
—
0
0
0
47
0.00
1.72
0.0
1.3
—
0.90
—
0
47
30
189
1.65
1.69
2.7
4.3
5.11
5.14
kpa
0.06
30
181
83
648
1.38
1.68
3.3
2.5
342.21
363.99
umol/l
0.99
68
558
14
69
2.07
1.67
1.2
1.2
141.00
330.87
ug/g
—
6
43
5
130
0.37
1.66
1.0
1.2
80.80
444.67
u/ml
—
5
120
27
418
0.61
1.66
1.1
1.3
35.02
37.35
iu/ml
—
5
129
76
587
1.38
1.64
1.9
1.8
1101.64
1200.40
nmol/l
0.29
60
451
27
167
1.67
1.64
8.3
8.1
15.79
15.63
%
0.10
27
161
36
240
1.56
1.63
3.0
3.8
7.39
7.34
ph
1.60
29
159
32
209
1.59
1.58
4.3
5.3
24.97
24.59
mmol/l
0.19
32
199
29
185
1.62
1.57
2.1
3.5
1.15
0.67
%
0.40
13
44
28
178
1.63
1.54
2.1
3.6
0.15
0.08
%
0.18
13
37
5
125
0.39
1.53
1.4
1.9
—
—
—
0
0
35
502
0.66
1.53
1.3
1.3
0.73
1.50
u/ml
—
10
134
196
1749
1.30
1.52
4.6
4.6
—
3.91
—
0
5
7
27
2.62
1.52
2.0
1.6
90.94
90.16
%
—
7
27
258
2394
1.38
1.52
28.9
16.1
47.68
25.85
mg/l
11.07
250
1957
166
1458
1.28
1.42
3.9
3.0
118.35
52.20
u/l
3.97
157
1352
207
2252
0.77
1.39
3.9
5.2
1.97
1.98
mu/l
0.04
183
2033
79
631
1.33
1.37
3.4
2.5
7.66
5.70
e6/l
0.44
74
576
0
38
0.00
1.35
0.0
1.3
—
0.65
—
0
10
6
131
0.45
1.31
1.2
1.4
—
45.57
—
0
7
5
19
2.65
1.22
1.0
1.2
25.08
25.81
ng/l
—
5
19
5
19
2.65
1.22
1.6
1.5
82.00
80.68
umol/l
—
5
19
5
20
2.52
1.15
3.6
2.2
—
—
—
0
0
135
1181
1.24
1.13
3.4
4.3
31.80
71.69
ng/l
0.86
107
918
0
29
0.00
0.98
0.0
1.0
—
—
—
0
0
13
77
1.72
0.96
1.1
1.2
1.41
1.53
ratio
—
6
50
26
184
1.45
0.94
2.1
3.7
0.10
0.03
%
—
10
36
21
298
0.68
0.90
1.1
1.3
464.00
631.58
titre
—
5
76
171
1855
0.83
0.88
3.3
4.0
15.18
15.14
pmol/l
0.06
148
1666
24
171
1.43
0.85
7.2
8.2
24.04
24.49
mmol/l
0.27
24
165
6
33
1.83
0.79
2.2
1.2
—
—
—
0
0
6
33
1.83
0.79
2.2
1.2
—
—
—
0
0
6
33
1.83
0.79
1.2
1.3
290.83
264.09
mosm/kgh2o
—
6
22
6
33
1.83
0.79
2.2
1.2
—
—
—
0
0
6
33
1.83
0.79
2.2
1.2
—
—
—
0
0
17
115
1.50
0.78
1.6
2.7
2.01
1.44
mmol/l
0.63
17
109
65
546
1.24
0.77
2.0
1.7
3.77
1.30
mg/l
2.65
59
436
6
34
1.78
0.76
3.0
2.3
6.09
4.66
e9/l
—
6
34
15
100
1.52
0.74
1.1
1.3
—
—
—
0
0
5
25
2.01
0.73
1.0
1.2
—
—
—
0
0
14
205
0.67
0.73
2.4
2.9
6.57
6.05
ph
1.83
14
146
34
424
0.78
0.67
1.5
1.3
2.37
2.85
g/l
1.15
22
244
7
43
1.64
0.67
1.0
1.1
—
—
—
0
0
23
174
1.35
0.61
1.4
2.5
1.89
1.16
%
1.38
23
174
5
30
1.68
0.61
1.0
1.7
9.84
10.46
%
—
5
30
5
30
1.68
0.61
1.2
1.3
30.80
32.37
pg
—
5
30
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
18
133
1.37
0.56
2.4
4.7
—
—
—
0
0
81
903
0.86
0.53
1.7
1.8
19.93
20.06
nmol/l
0.03
68
757
22
170
1.31
0.53
1.4
2.4
0.89
0.60
%
1.22
22
170
6
100
0.59
0.52
1.0
1.4
—
—
—
0
0
68
598
1.17
0.52
3.6
4.6
97.62
227.18
ng/l
0.84
63
512
48
558
0.83
0.52
3.5
2.9
0.78
0.84
ug/l
0.26
32
384
6
40
1.51
0.52
3.0
3.5
7.42
12.59
pmol/l
—
6
40
7
46
1.53
0.48
2.7
2.1
67.71
60.67
%
—
7
46
105
1141
0.88
0.47
2.2
2.5
71.01
80.51
nmol/l
2.32
87
1002
28
228
1.25
0.47
3.0
3.6
74.66
93.18
ng/l
0.97
23
197
5
82
0.60
0.46
1.0
1.5
—
—
—
0
0
25
201
1.26
0.46
2.6
3.6
—
—
—
0
0
13
172
0.74
0.42
1.2
1.2
—
—
—
0
0
123
1315
0.89
0.42
2.0
2.3
94.73
94.80
pmol/l
0.00
70
674
8
58
1.39
0.42
1.6
1.2
—
—
—
0
0
5
33
1.52
0.41
1.2
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
62.11
—
0
9
0
16
0.00
0.41
0.0
1.1
—
0.47
—
0
11
20
159
1.27
0.41
2.1
2.9
25.82
25.20
mmol/l
0.36
20
150
57
639
0.87
0.41
3.5
4.5
1.02
1.02
kg/l
0.77
43
422
8
60
1.34
0.40
1.1
1.1
—
118.33
—
0
6
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
179.76
—
0
18
55
488
1.15
0.39
3.1
3.6
—
—
—
0
0
256
2487
1.14
0.39
19.2
10.3
30.44
24.58
u/l
2.20
247
2387
257
2498
1.13
0.38
31.6
20.8
137.89
139.71
mmol/l
15.91
251
2437
20
161
1.26
0.38
2.1
2.5
—
—
—
0
0
6
41
1.47
0.36
6.0
2.5
10.22
11.02
mmol/l
—
6
41
257
2501
1.13
0.36
31.9
20.9
4.00
4.01
mmol/l
0.41
251
2436
22
181
1.23
0.35
1.5
1.3
—
—
—
0
0
26
218
1.21
0.35
1.3
1.6
—
—
—
0
0
6
45
1.34
0.34
1.2
1.1
—
—
—
0
0
12
92
1.31
0.32
1.3
1.3
—
—
—
0
0
237
2430
0.90
0.31
22.0
15.0
—
—
—
0
0
7
53
1.33
0.31
1.1
2.6
1.17
1.19
mmol/l
—
7
53
7
55
1.28
0.30
1.1
2.5
102.43
105.33
mmol/l
—
7
55
7
55
1.28
0.30
1.1
2.5
3.96
4.05
mmol/l
—
7
55
11
85
1.30
0.28
1.5
1.8
—
—
—
0
0
24
205
1.18
0.28
1.8
2.7
121.83
129.68
g/l
1.05
24
197
20
236
0.84
0.28
4.0
2.5
0.86
0.40
e6/l
0.39
20
217
5
38
1.32
0.23
1.2
3.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
258
2534
1.08
0.21
36.0
22.0
83.31
84.08
umol/l
0.13
252
2490
113
1080
1.07
0.20
3.2
3.9
6.18
6.26
ph
0.29
66
591
102
1063
0.94
0.18
2.8
3.4
1656.64
1757.68
ng/l
0.11
90
917
109
1133
0.94
0.18
2.9
2.9
308.67
127.82
ug/l
0.65
96
1029
61
646
0.93
0.17
1.8
1.9
485.93
436.06
pmol/l
0.27
47
530
98
1019
0.94
0.16
4.1
4.4
0.00
0.01
estimate
0.74
34
210
74
704
1.07
0.15
4.6
3.9
0.00
0.00
estimate
-0.00
34
209
14
121
1.16
0.15
1.5
1.3
1.07
1.09
g/l
0.06
14
113
13
150
0.86
0.15
1.2
1.3
—
—
—
0
0
80
768
1.05
0.13
4.1
4.1
0.00
0.00
estimate
-0.00
31
248
192
1885
1.04
0.12
35.6
19.8
14.90
13.78
%
11.34
192
1856
31
292
1.07
0.09
1.7
2.0
62.41
66.97
e9/l
0.32
20
219
31
293
1.06
0.08
1.9
1.8
—
—
—
0
0
31
294
1.06
0.07
2.0
2.7
2.71
7.10
ug/l
3.02
22
257
16
147
1.09
0.07
1.7
2.4
11.16
11.25
g/l
0.03
16
137
133
1350
0.97
0.06
3.8
4.3
0.00
0.03
estimate
0.79
35
264
9
102
0.88
0.06
9.4
9.5
—
—
—
0
0
130
1319
0.97
0.06
3.8
4.3
0.00
0.00
estimate
-0.00
37
272
132
1339
0.97
0.06
3.8
4.3
0.00
0.00
estimate
-0.00
37
280
258
2560
1.03
0.06
39.2
24.1
91.17
91.65
fl
0.64
252
2518
258
2561
1.03
0.05
39.3
24.1
4.11
4.43
e12/l
18.04
250
2481
258
2561
1.03
0.05
39.4
24.1
8.01
6.84
e9/l
7.60
249
2482
258
2561
1.03
0.05
39.3
24.1
274.80
239.55
e9/l
6.79
249
2495
258
2561
1.03
0.05
39.2
24.0
29.94
30.42
pg
2.67
252
2519
258
2561
1.03
0.05
39.7
24.5
36.85
39.84
%
17.82
252
2518
99
1007
0.97
0.05
4.5
4.4
2.76
2.17
ug/l
0.85
87
887
20
189
1.06
0.04
1.5
1.4
—
—
—
0
0
30
290
1.04
0.03
1.5
1.5
—
—
—
0
0
10
93
1.08
0.02
1.1
1.2
—
—
—
0
0
12
118
1.02
0.00
2.0
2.1
479.92
686.82
ug/l
0.19
12
111
18
175
1.03
0.00
1.4
1.4
—
—
—
0
0
25
249
1.00
0.00
2.8
1.7
399.32
386.47
nmol/l
0.08
25
224
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
8.3
—
7.26
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
8.25
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.4
—
25.13
—
0
8
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
5
50
1.00
-0.00
1.0
1.2
24.94
16.72
u/l
—
5
45
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
75
0.93
-0.00
1.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
6.4
—
0.69
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
47.57
—
0
7
9
90
1.00
-0.00
3.0
4.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.4
—
0.00
—
0
5
0
6
0.00
-0.00
0.0
2.0
—
18.50
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_DIGESTIVE_ORGANS_NAS – Malignant neoplasm of other and ill-defined digestive organs

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).